Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Rebates: Talking Points Continue, But Deficit Deal Elusive

This article was originally published in RPM Report

Executive Summary

Once again the President is calling for rebates on prescription drugs sold under Medicare Part D. But without a big deficit deal involving entitlement reform, is there any way to enact them?

You may also be interested in...



Part D Rebates And Some New Health Policy Proposals Get Deficit Reduction Estimates In CBO Report

The most recent Congressional Budget Office list of deficit-reducing options includes some familiar items as well as five new approaches to changing health care programs, such as tax-related changes to employer-sponsored insurance.

Obama Pitches Part D Rx Price Concessions In State Of The Union Address

President Obama’s speech includes some proposals for cost-savings in Medicare, such as having wealthier seniors pay more, moving from pay-for-service to pay-for-performance and mandatory rebates on drugs used in Medicare Part D, which drew a quick response from PhRMA.

Merck CEO Frazier Stands Alone As Pharma Signatory Urging Fiscal Cliff Budget Deal

Coalition of business leaders that includes Merck CEO Ken Frazier pushes for deficit deal to avert sequestration. The reason seems simple: corporate tax reform.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS081100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel